Field Notes/Support : Pharma
Urea ํฌ๋ฆผ์ด ๋ณด์Šต์ œ์ด์ž ๊ฐ์งˆ์šฉํ•ด์ œ๋กœ ์“ฐ์ผ ์ˆ˜ ์žˆ๋Š” ์ด์œ ?
2025.04.26
๐Ÿ’ง Urea ํฌ๋ฆผ ์ž‘์šฉ๊ธฐ์ „โœ… 1. ๋ณด์Šต ์ž‘์šฉ (Humectant, ์ €๋†๋„: 5~10%)urea๋Š” **์ฒœ์—ฐ ๋ณด์Šต ์ธ์ž(NMF, Natural Moisturizing Factor)**์˜ ์ผ์ข…ํ”ผ๋ถ€์˜ ๊ฐ์งˆ์ธต(corneocytes)์— ์ˆ˜๋ถ„์„ ๋Œ์–ด๋‹น๊ฒจ ์ˆ˜๋ถ„ ์œ ์ง€→ ํ”ผ๋ถ€ ์ˆ˜๋ถ„ ์žฅ๋ฒฝ ํšŒ๋ณต→ ๊ฑด์กฐ์ฆ, ์•„ํ† ํ”ผ, ๋…ธ์ธ ํ”ผ๋ถ€์— ์œ ์šฉโœ… 2. ๊ฐ์งˆ์šฉํ•ด ์ž‘์šฉ (Keratolytic, ๊ณ ๋†๋„: 20% ์ด์ƒ)๊ณ ๋†๋„ urea๋Š” ๋‹จ๋ฐฑ์งˆ ๊ตฌ์กฐ๋ฅผ ๋ถ„ํ•ดํ•˜๊ฑฐ๋‚˜ ๋ณ€์„ฑ์‹œ์ผœ→ ๊ฐ์งˆ์„ธํฌ(keratin)์˜ ๊ฒฐํ•ฉ๋ ฅ ์•ฝํ™” → ๊ฐ์งˆ์ด ๋–จ์–ด์ ธ ๋‚˜๊ฐ€๊ฒŒ ํ•จ→ ๊ฑด์„ , ์–ด๋ฃจ๋Ÿฌ๊ธฐ, ์†๋ฐœ๋ฐ”๋‹ฅ์˜ ๋‘๊บผ์šด ๊ฐ์งˆ์— ์‚ฌ์šฉโœ… 3. ํ”ผ๋ถ€ ์นจํˆฌ ์ด‰์ง„ (Penetration enhancer)urea๋Š” ๊ฐ์งˆ์ธต์„ ์œ ์—ฐํ•˜๊ฒŒ ๋งŒ๋“ค์–ด ๋‹ค๋ฅธ ์•ฝ๋ฌผ์˜ ํ”ผ๋ถ€ ์นจํˆฌ๋„ ๋†’์ž„→ ๋ณตํ•ฉ์ œํ˜•์— ์‚ฌ์šฉ ์‹œ ํ™œ์„ฑ์„ฑ๋ถ„..
Field Notes/Support : Pharma
Colchicine๋ฅ˜ tubulin ์–ต์ œ์ œ์˜ ์ž‘์šฉ๊ธฐ์ „
2025.04.26
๐Ÿ’ก Colchicine ๋ฅ˜ Tubulin ์–ต์ œ์ œ์˜ ์ž‘์šฉ๊ธฐ์ „โœ… 1. Colchicine binding site์— ๊ฒฐํ•ฉColchicine์€ α/β-tubulin ์ดํ•ฉ์ฒด์˜ β-subunit์— ๊ฒฐํ•ฉ๊ฒฐํ•ฉ ๋ถ€์œ„: Colchicine binding site (distinct from taxane or vinca sites)โœ… 2. Microtubule polymerization ์–ต์ œ๊ฒฐํ•ฉ ํ›„, tubulin ์ดํ•ฉ์ฒด๊ฐ€ ์˜ฌ๋ฐ”๋ฅด๊ฒŒ ๋ฏธ์„ธ์†Œ๊ด€์„ ํ˜•์„ฑํ•˜์ง€ ๋ชปํ•จ→ microtubule polymerization ์–ต์ œ→ ์„ธํฌ ๊ณจ๊ฒฉ ์œ ์ง€ ๋ฐ mitotic spindle ํ˜•์„ฑ ๋ฐฉํ•ดํŠนํžˆ **M๊ธฐ(M phase)**์—์„œ ์„ธํฌ ๋ถ„์—ด ์ค‘์ง€ → ์„ธํฌ์‚ฌ๋ฉธ(apoptosis) ์œ ๋„โœ… 3. ์—ผ์ฆ์„ธํฌ ์ด๋™ ๋ฐ ํ™œ์„ฑ ์–ต์ œ (ํŠนํžˆ neutrophils)..
Field Notes/Support : Pharma
NF-κB(Nuclear Factor kappa-light-chain-enhancer of activated B cells) ํ•˜์œ„์‹ ํ˜ธ
2025.04.26
**NF-κB(Nuclear Factor kappa-light-chain-enhancer of activated B cells)**๋Š” ๋ฉด์—ญ, ์—ผ์ฆ, ์„ธํฌ ์ƒ์กด ๋“ฑ์— ์ค‘์š”ํ•œ ์—ญํ• ์„ ํ•˜๋Š” **์ „์‚ฌ์ธ์ž(transcription factor)**์ด๊ณ , ๊ทธ ๊ฒฝ๋กœ๋Š” canonical๊ณผ non-canonical๋กœ ๋‚˜๋‰˜์–ด์ง. ๐Ÿงฌ NF-κB Signaling Pathwaysโœ… 1. Canonical NF-κB Pathway๐Ÿ”น ์ฃผ์š” ํŠน์ง•๋น ๋ฅด๊ฒŒ ๋ฐ˜์‘ํ•˜๋Š” pathway (์ˆ˜ ๋ถ„ ๋‚ด)๋‹ค์–‘ํ•œ ๋ฉด์—ญ, ์—ผ์ฆ ๋ฐ˜์‘์— ์ฆ‰๊ฐ ๋Œ€์‘๋Œ€๋ถ€๋ถ„์˜ **์„ ์ฒœ๋ฉด์—ญ ์ž๊ทน(TNF-α, IL-1, TLR ๋“ฑ)**์— ์˜ํ•ด ์œ ๋„๐Ÿ”น ํ™œ์„ฑํ™” ์ž๊ทนTNF-αIL-1βTLR (Toll-like receptors)LPS (lipopolysaccharide)๐Ÿ”น ์ฃผ์š”..
Field Notes/Support : Pharma
Tubulin์„ ํƒ€๊ฒŸํ•˜๋Š” ํ•ญ์•”์ œ
2025.04.26
**ํŠœ๋ทธ๋ฆฐ(tubulin)**์€ ์„ธํฌ ๋ถ„์—ด ์ค‘ **๋ฏธ์„ธ์†Œ๊ด€(microtubule)**์„ ํ˜•์„ฑํ•˜๋Š” ๋‹จ๋ฐฑ์งˆ์ด๋ผ, ํ•ญ์•”์ œ์˜ ์ฃผ์š” ํƒ€๊ฒŸ์ด ๋จ.์„ธํฌ ๋ถ„์—ด์„ ๋ง‰์•„ ์•”์„ธํฌ ์ฆ์‹์„ ์ฐจ๋‹จํ•˜๋Š” ์ „๋žต์ธ๋ฐ, ์ฃผ๋กœ mitotic spindle ํ˜•์„ฑ ์–ต์ œ๋ฅผ ํ†ตํ•ด ์ž‘๋™ํ•จ.๐Ÿงฌ Tubulin-targeting Anticancer Drugsโœ… 1. Microtubule polymerization ์–ต์ œ์ œ (ํŠœ๋ทธ๋ฆฐ ์ค‘ํ•ฉ ์ €ํ•ด์ œ)๐Ÿ‘‰ tubulin dimer๊ฐ€ polymerizationํ•˜๋Š” ๊ฑธ ๋ง‰์Œ๐Ÿ”น ๋Œ€ํ‘œ ์•ฝ๋ฌผ: Vinca alkaloidsVincristineVinblastineVinorelbineVindesine๐Ÿ”น ๊ธฐ์ „tubulin์˜ β-subunit์— ๊ฒฐํ•ฉ → microtubule ํ˜•์„ฑ ์–ต์ œmitotic spindle ํ˜•์„ฑ์ด ์•ˆ ๋ผ..
Field Notes/Support : Pharma
์•„ํ† ํ”ผ์น˜๋ฃŒ์ œ ์ค‘ ์‹œ๋นˆ์ฝ”(spesolimab)์™€ ๋น„ํƒ€๋งˆ(tapinarof) ๋น„๊ต, AHR ์ž‘์šฉ์ œ์˜ ๋ฉ”์ปค๋‹ˆ์ฆ˜
2025.04.26
1. ์‹œ๋นˆ์ฝ”(Spevigo, ์„ฑ๋ถ„๋ช…: ์Šคํ”„๋ ˆ์†Œํ‹ฐ๋ง™ / spesolimab)์•ฝ๋ฌผ ์ข…๋ฅ˜: ์ธ๊ฐ„ํ™” ๋‹จํด๋ก ํ•ญ์ฒด (anti-IL-36 receptor antibody)๊ธฐ์ „:์‹œ๋นˆ์ฝ”๋Š” IL-36 receptor๋ฅผ ์ฐจ๋‹จํ•˜์—ฌ IL-36 ๊ฒฝ๋กœ์˜ ๊ณผํ™œ์„ฑ์„ ์–ต์ œํ•จ.์ด ๊ฒฝ๋กœ๋Š” ์—ผ์ฆ์„ฑ ํ”ผ๋ถ€์งˆํ™˜, ํŠนํžˆ **๋ฒ”๋ฐœ์„ฑ ๋†ํฌ์„ฑ ๊ฑด์„ (GPP, generalized pustular psoriasis)**์—์„œ ์ค‘์š”ํ•œ ์—ญํ• ์„ ํ•จ.์ ์‘์ฆ (FDA ์Šน์ธ):ํ˜„์žฌ ์•„ํ† ํ”ผ ํ”ผ๋ถ€์—ผ์ด ์•„๋‹Œ, GPP์˜ ๊ธ‰์„ฑ ๋ฐœํ˜„ ์น˜๋ฃŒ์ œ๋กœ FDA ์Šน์ธ ๋ฐ›์Œ (2022๋…„).์•„ํ† ํ”ผ์™€์˜ ์—ฐ๊ด€์„ฑ:์•„ํ† ํ”ผ ํ”ผ๋ถ€์—ผ ์น˜๋ฃŒ์ œ๋กœ ์ง์ ‘ ์‚ฌ์šฉ๋˜์ง„ ์•Š์ง€๋งŒ, IL-36 ๊ฒฝ๋กœ๊ฐ€ ์ค‘์ฆ ์—ผ์ฆ์„ฑ ํ”ผ๋ถ€์งˆํ™˜์—์„œ ๊ณตํ†ต์ ์œผ๋กœ ํ™œ์„ฑํ™”๋œ๋‹ค๋Š” ์ ์—์„œ ์—ฐ๊ตฌ ์ค‘.์•„ํ† ํ”ผ ํ™˜์ž ์ค‘ ์ผ๋ถ€์—์„œ IL-36 ์‹ ํ˜ธ ๊ฒฝ๋กœ๊ฐ€ ๊ณผํ™œ์„ฑํ™”๋œ ๊ฒฝ..
Field Notes/Support : Pharma
๋ฐฑ๊ธˆ๊ณ„ ํ•ญ์•”์ œ์˜ ๊ตฌ์กฐ์— ๋”ฐ๋ผ ๋…์„ฑ์ด ๋‹ค๋ฅธ ์ด์œ ?
2025.04.26
๋ฐฑ๊ธˆ๊ณ„ ํ•ญ์•”์ œ(platinum-based agents)๋Š” ์„ธํฌ๋…์„ฑ ํ•ญ์•”์ œ ์ค‘ **์•Œํ‚ฌํ™”์ œ(alkylating-like agents)**์— ์†ํ•˜๋ฉฐ, DNA์— ์ง์ ‘ ์ž‘์šฉํ•ด ์•”์„ธํฌ ์‚ฌ๋ฉธ์„ ์œ ๋„ํ•จ. ๋Œ€ํ‘œ์ ์ธ ์•ฝ๋ฌผ์—๋Š” cisplatin, carboplatin, oxaliplatin์ด ์žˆ์Œ.๋ฐฑ๊ธˆ๊ณ„ ํ•ญ์•”์ œ์˜ ์•ฝ๋ฌผํ•™์  ๊ธฐ์ „ (Mechanism of Action)1. DNA์™€์˜ ๊ณต์œ ๊ฒฐํ•ฉ ํ˜•์„ฑ (Covalent binding to DNA)๋ฐฑ๊ธˆ๊ณ„ ์•ฝ๋ฌผ์€ ์ˆ˜ํ™”(hydrolysis) ๊ณผ์ •์„ ํ†ตํ•ด ํ™œ์„ฑํ™”๋จ.์˜ˆ: Cisplatin์€ ์ฒด๋‚ด์—์„œ Cl- ์ด์˜จ์ด ๋‚ฎ์€ ํ™˜๊ฒฝ(์„ธํฌ ๋‚ด)์—์„œ **์•„์ฟ ์•„ํ”Œ๋ผํ‹ด(aquated form)**์œผ๋กœ ์ „ํ™˜๋จ.ํ™œ์„ฑํ™”๋œ ํ˜•ํƒœ๋Š” DNA์˜ N7 guanine ์—ผ๊ธฐ์— ๊ณต์œ ๊ฒฐํ•ฉ์„ ํ˜•์„ฑํ•จ.2. DNA ๊ต์ฐจ๊ฒฐํ•ฉ(cro..
Field Notes/Support : Pharma
B์„ธํฌ ๋ถ„ํ™”๋‹จ๊ณ„์— ๋”ฐ๋ผ ๋‹ฌ๋ผ์ง€๋Š” ํ‘œ์ง€์ž, ๊ทธ์— ๋”ฐ๋ฅธ ํ•ญ์ฒด ์•ฝ๋ฌผ ๋น„๊ต
2025.04.26
๐Ÿงฌ B์„ธํฌ ๋ถ„ํ™” & ํ‘œ์ง€์ž ์ •๋ฆฌํ‘œ๋ถ„ํ™” ๋‹จ๊ณ„์ฃผ์š” ํ‘œ์ง€์ž์„ค๋ช…๋Œ€ํ‘œ ์•ฝ๋ฌผ ์˜ˆ์‹œ์ „๊ตฌ B์„ธํฌ (Pro-B)CD34, CD10, CD19, TdT๊ณจ์ˆ˜ ๋‚ด B์„ธํฌ ์ดˆ๊ธฐ๋‹จ๊ณ„- B-ALL ๊ด€๋ จ (์˜ˆ: Blinatumomab ํƒ€๊ฒŸ: CD19)์ „B์„ธํฌ (Pre-B)CD10, CD19, CD22, TdT์ „B์„ธํฌ ์ˆ˜์šฉ์ฒด ํ˜•์„ฑ ์‹œ๊ธฐ ๋ฏธ์„ฑ์ˆ™ B์„ธํฌCD19, CD20(์‹œ์ž‘), IgM๋ง์ดˆ๋กœ ์ด๋™ ๊ฐ€๋Šฅํ•ด์ง ์„ฑ์ˆ™ B์„ธํฌCD19, CD20, CD21, CD22, IgM/IgD๋ง์ดˆ ๋ฆผํ”„์ ˆ ์กด์žฌ, ํ•ญ์› ๋ฐ˜์‘ ๊ฐ€๋ŠฅRituximab (CD20), Obinutuzumab ๋“ฑํ™œ์„ฑํ™” B์„ธํฌCD19, CD20, CD27ํ•ญ์› ๋…ธ์ถœ ํ›„ ๋ฐ˜์‘ ์œ ๋„ ํ˜•์งˆ์„ธํฌ (Plasma)CD38↑↑, CD138, CD319, MHC Iํ•ญ์ฒด ๋ถ„๋น„์„ธํฌ, CD20 ์†Œ์‹ค๋จDarat..
Field Notes/Support : Pharma
B์„ธํฌ๋ฆผํ”„์ข…๊ณผ ๋‹ค๋ฐœ์„ฑ๊ณจ์ˆ˜์ข…์˜ B์„ธํฌ ์ƒํƒœ๊ฐ€ ๋‹ค๋ฅด๋‹ค?
2025.04.26
๐Ÿงฌ 1. B์„ธํฌ ๋ฆผํ”„์ข… = ์„ฑ์ˆ™ B์„ธํฌ์—์„œ ๋ฐœ์ƒ๊ธฐ์›: ๋Œ€๋ถ€๋ถ„ germinal center B์„ธํฌ๋‚˜ post-germinal B์„ธํฌ→ ์•„์ง ํ˜•์งˆ์„ธํฌ๋กœ ์™„์ „ํžˆ ๋ถ„ํ™”๋˜๊ธฐ ์ „ ๋‹จ๊ณ„๊ทธ๋ž˜์„œ CD20, CD19 ๋“ฑ์ด ๊ฐ•ํ•˜๊ฒŒ ๋ฐœํ˜„๋จ๐Ÿ‘‰ Rituximab ํƒ€๊ฒŸ (CD20)๐Ÿ”ฅ ์งˆํ™˜ ์˜ˆ์‹œ:DLBCL (Diffuse Large B Cell Lymphoma)Follicular lymphomaMantle cell lymphomaCLL/SLL (๋งŒ์„ฑ ๋ฆผํ”„๊ตฌ์„ฑ ๋ฐฑํ˜ˆ๋ณ‘/์†Œ๋ฆผํ”„๊ตฌ ๋ฆผํ”„์ข…) ๋“ฑ๐Ÿ“Œ โœ… ์ด๋“ค์€ ๋น ๋ฅด๊ฒŒ ์ฆ์‹ํ•˜๊ฑฐ๋‚˜, ๋ฆผํ”„์ ˆ ๋“ฑ์—์„œ ์ฆ์‹์ด ์ •์ฒด๋œ ์ƒํƒœ๋กœ ์กด์žฌ→ ๋ถ„ํ™”๊ฐ€ ๋œ ๋˜์–ด ํ˜•์งˆ์„ธํฌ๊นŒ์ง€ ๋ชป ๊ฐ๐Ÿงฌ 2. ๋‹ค๋ฐœ์„ฑ ๊ณจ์ˆ˜์ข… = ํ˜•์งˆ์„ธํฌ(Plasma cell)์—์„œ ๋ฐœ์ƒ๊ธฐ์›: ์™„์ „ํžˆ ๋ถ„ํ™”๋œ plasma cell→ ํ•ญ์ฒด๋ฅผ ๋ถ„๋น„ํ•˜๋Š” ์ƒํƒœ..
Field Notes/Support : Pharma
B์„ธํฌ๋ฅผ ํƒ€๊ฒŸํ•˜๋Š” Rituximab์€ CD20, Daratumumab์€ CD38์„ ํƒ€๊ฒŸํ™”๋Š” ์ด์œ ?
2025.04.26
๋‘˜ ๋‹ค B์„ธํฌ ๊ด€๋ จ ํ•ญ์ฒด์ธ๋ฐ ์™œ ์“ฐ๋Š” ์งˆํ™˜์ด ๋‹ค๋ฅธ๊ฐ€?→ ์ด๊ฑด CD20๊ณผ CD38์ด ๋ฐœํ˜„๋˜๋Š” B์„ธํฌ์˜ "๋ถ„ํ™”๋‹จ๊ณ„"๊ฐ€ ๋‹ค๋ฅด๊ธฐ ๋•Œ๋ฌธ์ด์—์š”. ๐Ÿ‘‡๐Ÿ”ฌ B์„ธํฌ ๋ถ„ํ™” ํ๋ฆ„ ํ•œ๋ˆˆ์— ๋ณด๊ธฐcss๋ณต์‚ฌํŽธ์ง‘์กฐํ˜ˆ๋ชจ์„ธํฌ → ์ „๊ตฌ B์„ธํฌ (pro-B cell) → ์ „B์„ธํฌ (pre-B cell) → ๋ฏธ์„ฑ์ˆ™ B์„ธํฌ → ์„ฑ์ˆ™ B์„ธํฌ (CD20 ๋ฐœํ˜„ ์‹œ์ž‘) → ํ˜•์งˆ์„ธํฌ(plasma cell) (CD20 ์—†์Œ, CD38↑↑) ๐Ÿงฌ 1. CD20 = ์„ฑ์ˆ™ํ•œ B์„ธํฌ์—๋งŒ ๋ฐœํ˜„๋ฐœํ˜„ ์œ„์น˜: ์ „B์„ธํฌ ์ดํ›„ ~ ์„ฑ์ˆ™ B์„ธํฌ๊นŒ์ง€ํ˜•์งˆ์„ธํฌ(plasma cell)์—์„œ๋Š” ๋ฐœํ˜„ โŒ๐Ÿ‘‰ ๊ทธ๋ž˜์„œ Rituximab์€:๋น„ํ˜ธ์ง€ํ‚จ B์„ธํฌ ๋ฆผํ”„์ข…CLL (๋งŒ์„ฑ ๋ฆผํ”„๊ตฌ์„ฑ ๋ฐฑํ˜ˆ๋ณ‘)์ž๊ฐ€๋ฉด์—ญ ์งˆํ™˜ (RA ๋“ฑ)→ **"์„ฑ์ˆ™ B์„ธํฌ ๊ธฐ๋ฐ˜ ์งˆํ™˜"**์— ์‚ฌ์šฉ๋จ๐Ÿ”ฌ 2. CD38 = ํ˜•์งˆ์„ธ..
Field Notes/Support : Pharma
ํ•ญ์ฒด๊ฐ€ ์ˆ˜์šฉ์ฒด์— ๊ฒฐํ•ฉํ–ˆ์„ ๋•Œ ์ผ์–ด๋‚˜๋Š” ๋‘ ๊ฐ€์ง€ ์ฃผ์š” ๋ฐ˜์‘
2025.04.26
โœ… ํ•ญ์ฒด๊ฐ€ ์ˆ˜์šฉ์ฒด์— ๊ฒฐํ•ฉํ–ˆ์„ ๋•Œ ์ผ์–ด๋‚˜๋Š” ๋‘ ๊ฐ€์ง€ ์ฃผ์š” ๋ฐ˜์‘ ํ๋ฆ„1. ๋ฉด์—ญ์„ธํฌ๋ฅผ ๋ถˆ๋Ÿฌ์˜ค๋Š” ๋ฐฉ์‹ (ADCC, CDC ๋“ฑ)= ํ•ญ์ฒด์˜ Fc ๋ถ€๋ถ„์ด ๋ฉด์—ญ๊ณ„์™€ ์ƒํ˜ธ์ž‘์šฉํ•ด์„œ ์„ธํฌ๋ฅผ ์™ธ๋ถ€์—์„œ ์ œ๊ฑฐํ•˜๋Š” ๋ฐฉ์‹๐Ÿงฉ ์ž‘๋™ ์›๋ฆฌ:ํ•ญ์ฒด๊ฐ€ ์„ธํฌ ํ‘œ๋ฉด์˜ ํ•ญ์›(์ˆ˜์šฉ์ฒด ๋“ฑ)์— ๊ฒฐํ•ฉํ•ญ์ฒด์˜ Fc ๋ถ€์œ„๋ฅผ ์ธ์‹ํ•˜๋Š” ๋ฉด์—ญ์„ธํฌ (NK์„ธํฌ, ๋Œ€์‹์„ธํฌ, ๋ณด์ฒด ๋“ฑ) ํ™œ์„ฑํ™”→ ADCC (ํ•ญ์ฒด์˜์กด ์„ธํฌ๋…์„ฑ): NK์„ธํฌ๊ฐ€ perforin, granzyme ๋ถ„๋น„ํ•ด์„œ ํƒ€๊นƒ์„ธํฌ ์ฃฝ์ž„→ CDC (๋ณด์ฒด์˜์กด ์„ธํฌ์šฉํ•ด): ๋ณด์ฒด ์‹œ์Šคํ…œ ํ™œ์„ฑํ™” → ์„ธํฌ๋ง‰ ๊ตฌ๋ฉ ๋šซ์–ด ์ฃฝ์ž„๐Ÿ“Œ ๋Œ€ํ‘œ ์•ฝ๋ฌผ:Rituximab (CD20)Trastuzumab (HER2)Daratumumab (CD38)Cetuximab (EGFR)2. ์‹ ํ˜ธ์ „๋‹ฌ/์„ธํฌ์‚ฌ ์œ ๋„ (ํด๋Ÿฌ์Šคํ„ฐ๋ง or ์ˆ˜์šฉ์ฒด ๊ธฐ๋Šฅ ์ฐจ๋‹จ)= ..
Field Notes/Support : Pharma
ํ•ญ์ฒด ์œ ๋„ ํด๋Ÿฌ์Šคํ„ฐ๋ง์„ ์ด์šฉํ•˜๋Š” ๋˜ ๋‹ค๋ฅธ ์•ฝ, rituximab๊ณผ trastuzumab
2025.04.26
๐Ÿงฌ 1. Rituximab (๋ฆฌํˆญ์‹œ๋ง™)ํ•ญ๋ชฉ๋‚ด์šฉ์ ์‘์ฆB์„ธํฌ ๋ฆผํ”„์ข…, ๋งŒ์„ฑ ๋ฆผํ”„๊ตฌ์„ฑ ๋ฐฑํ˜ˆ๋ณ‘(CLL), ๋ฅ˜๋งˆํ‹ฐ์Šค ๊ด€์ ˆ์—ผ ๋“ฑํ‘œ์ CD20 (B์„ธํฌ ํ‘œ๋ฉด ํ•ญ์›)ํ•ญ์ฒด ํƒ€์ž…Chimeric IgG1 (๋งˆ์šฐ์Šค + ์ธ๊ฐ„)์ž‘์šฉ๊ธฐ์ „ โ‘  ADCC: NK์„ธํฌ๊ฐ€ FcγR ํ†ตํ•ด B์„ธํฌ ํŒŒ๊ดด โ‘ก CDC: ๋ณด์ฒด ํ™œ์„ฑํ™”๋กœ B์„ธํฌ ์šฉํ•ด โ‘ข Apoptosis ์œ ๋„: CD20 clustering์ด ์„ธํฌ์‚ฌ ์œ ๋„ โ‘ฃ B์„ธํฌ ์ œ๊ฑฐ → ์ž๊ฐ€๋ฉด์—ญ ์งˆํ™˜ ์กฐ์ ˆ์—๋„ ์‚ฌ์šฉ ๐Ÿ”Ž CD20์€ B์„ธํฌ์˜ ์„ฑ์ˆ™๋‹จ๊ณ„์—์„œ ๋ฐœํ˜„๋˜๋Š” ๋งˆ์ปค๋กœ, ์ •์ƒ B์„ธํฌ์™€ ์ข…์–‘์„ฑ B์„ธํฌ ๋ชจ๋‘๋ฅผ ์ œ๊ฑฐํ•จ → B์„ธํฌ ๊ธฐ๋ฐ˜ ์งˆํ™˜์— ๋งค์šฐ ํšจ๊ณผ์ ๐Ÿงฌ 2. Trastuzumab (ํŠธ๋ผ์ŠคํŠธ์ฃผ๋ง™)ํ•ญ๋ชฉ๋‚ด์šฉ์ ์‘์ฆHER2+ ์œ ๋ฐฉ์•”, HER2+ ์œ„์•”ํ‘œ์ HER2 (ERBB2), ์„ธํฌ๋ง‰ ์ˆ˜์šฉ์ฒดํ˜• tyrosine ki..
Field Notes/Support : Pharma
CD38์— ํ•ญ์ฒด ๋‹ค์ž˜๋ ‰์Šค๊ฐ€ ๋ถ™์œผ๋ฉด ์™œ ํด๋Ÿฌ์Šคํ„ฐ๋ง์ด ์ผ์–ด๋‚˜๋Š”๊ฐ€?
2025.04.26
๐Ÿ”— 1. ํด๋Ÿฌ์Šคํ„ฐ๋ง(clustering)์ด๋ž€?๋จผ์ € ์šฉ์–ด๋ถ€ํ„ฐ ์งš๊ณ  ๊ฐ€๋ฉด,ํด๋Ÿฌ์Šคํ„ฐ๋ง = ์„ธํฌ ํ‘œ๋ฉด์— ํฉ์–ด์ ธ ์žˆ๋˜ ์ˆ˜์šฉ์ฒด(์˜ˆ: CD38)๋“ค์ด ํ•œ ์ง€์ ์— ๋ชจ์—ฌ์„œ ์‘์ง‘๋˜๋Š” ํ˜„์ƒ์ด๊ฑด ํ•ญ์ฒด๊ฐ€ ๊ฒฐํ•ฉํ•  ๋•Œ ์ž์ฃผ ์ผ์–ด๋‚˜๋Š” ์ผ์ž…๋‹ˆ๋‹ค. ์™œ ๊ทธ๋Ÿด๊นŒ์š”?๐Ÿงฒ 2. ํ•ญ์ฒด์˜ ๊ตฌ์กฐ์  ํŠน์„ฑ ๋•Œ๋ฌธํ•ญ์ฒด๋Š” ๊ตฌ์กฐ์ ์œผ๋กœ Y์žํ˜•์ด๊ณ , **ํ•ญ์› ๊ฒฐํ•ฉ ๋ถ€์œ„(Fab)**๊ฐ€ ๋‘ ๊ฐœ ์žˆ์–ด์š”.→ ์ฆ‰, ํ•ญ์ฒด ํ•˜๋‚˜๊ฐ€ CD38 ๋‘ ๊ฐœ์— ๋™์‹œ์— ๊ฒฐํ•ฉํ•  ์ˆ˜ ์žˆ์Œ→ ์„œ๋กœ ๋‹ค๋ฅธ CD38 ๋‹จ๋ฐฑ์งˆ์„ ๋ฌผ๋ฆฌ์ ์œผ๋กœ ๋Œ์–ด๋‹น๊ฒจ ์—ฐ๊ฒฐ์‹œํ‚ด→ ์ด๊ฒŒ cross-linking → clustering์œผ๋กœ ์ด์–ด์ง๐Ÿ“Œ **์ด๊ฑธ “ํ•ญ์ฒด ์œ ๋„ ๋‹ค๋ฐœ์„ฑ ์ˆ˜์šฉ์ฒด ์‘์ง‘ (antibody-induced receptor oligomerization)”**์ด๋ผ๊ณ  ๋ถ€๋ฅด๊ธฐ๋„ ํ•ด์š”.๐Ÿ”ฌ 3. CD38์€ ๋‹จ์ˆœํ•œ ํ‘œ์ง€ ..
Field Notes/Support : Pharma
ํ•ญ์ฒด๊ธฐ๋ฐ˜ ํ•ญ์•”์ œ(ํ‚คํŠธ๋ฃจ๋‹ค, ์˜ต๋””๋ณด, ์—ฌ๋ณด์ด, ๋‹ค์ž˜๋ ‰์Šค) ๋น„๊ต
2025.04.26
1. ํ‚คํŠธ๋ฃจ๋‹ค (Keytruda, ์„ฑ๋ถ„๋ช…: pembrolizumab)๊ธฐ์ „:PD-1 (Programmed Death-1) ์–ต์ œ์ œ.T์„ธํฌ ํ‘œ๋ฉด์˜ PD-1 ์ˆ˜์šฉ์ฒด๊ฐ€ ์•”์„ธํฌ์˜ PD-L1๊ณผ ๊ฒฐํ•ฉํ•˜๋ฉด ๋ฉด์—ญ๋ฐ˜์‘์ด ์–ต์ œ๋จ. Pembrolizumab์€ PD-1์„ ์ฐจ๋‹จํ•ด T์„ธํฌ๊ฐ€ ์•”์„ธํฌ๋ฅผ ๊ณต๊ฒฉํ•˜๋„๋ก ํ•จ.์ข…๋ฅ˜:๋ฉด์—ญ๊ด€๋ฌธ์–ต์ œ์ œ (Immune Checkpoint Inhibitor)์ ์‘์ฆ:๋น„์†Œ์„ธํฌํ์•”(NSCLC), ํ‘์ƒ‰์ข…, ํ˜ธ์ง€ํ‚จ๋ฆผํ”„์ข…, ์š”๋กœ์ƒํ”ผ์•”, MSI-H ๊ณ ํ˜•์•” ๋“ฑ ๋‹ค์ˆ˜.ํŠน์ง•:ํ•ญ์•”์ œ ์ค‘์—์„œ๋„ ์ ์‘์ฆ์ด ๋น ๋ฅด๊ฒŒ ํ™•๋Œ€๋œ ์•ฝ๋ฌผ.์ข…์–‘์ด PD-L1 ๋ฐœํ˜„์ด ๋†’์„์ˆ˜๋ก ํšจ๊ณผ๊ฐ€ ์ข‹์Œ.๋ฉด์—ญ๊ด€๋ จ ๋ถ€์ž‘์šฉ (๋ฉด์—ญ ๊ด€๋ จ ๊ฐ„์—ผ, ๊ฐ‘์ƒ์„  ๊ธฐ๋Šฅ ์ด์ƒ ๋“ฑ)์ด ์žˆ์„ ์ˆ˜ ์žˆ์Œ.2. ์˜ต๋””๋ณด (Opdivo, ์„ฑ๋ถ„๋ช…: nivolumab)๊ธฐ์ „:์—ญ์‹œ PD-1 ์–ต์ œ์ œ.Pe..
Field Notes/Support : Pharma
ํ•ญ์ฒด๋Š” ์ˆ˜์šฉ์ฒด์— ๋ถ™๊ธฐ๋งŒ ํ•ด๋„ ์„ธํฌ๋‚ด ์‹ ํ˜ธ์ „๋‹ฌ์„ ํ•˜๋Š”๊ฐ€?
2025.04.26
โœ… A. ํ•ญ์ฒด๊ฐ€ ๋ถ™๊ธฐ๋งŒ ํ•ด๋„ ๋‚ด๋ถ€ ์‹ ํ˜ธ๋ฅผ ์œ ๋„ํ•  ์ˆ˜ ์žˆ์„๊นŒ?๊ทธ๋Ÿด ์ˆ˜ ์žˆ์–ด์š”.ํ•ญ์ฒด๊ฐ€ ์„ธํฌ ํ‘œ๋ฉด ์ˆ˜์šฉ์ฒด(antigen)์— ๊ฒฐํ•ฉํ•˜๋ฉด, ๊ทธ ์ˆ˜์šฉ์ฒด์˜ **๊ตฌ์กฐ์  ๋ณ€ํ™”๋‚˜ ํด๋Ÿฌ์Šคํ„ฐ๋ง(์‘์ง‘)**์„ ์œ ๋„ํ•˜๋ฉด์„œ ์„ธํฌ ๋‚ด๋ถ€์— ์‹ ํ˜ธ ์ „๋‹ฌ์„ ์ด‰๋ฐœํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.๐Ÿ”ฌ B. ๋‹ค์ž˜๋ ‰์Šค๊ฐ€ ์œ ๋„ํ•˜๋Š” ์ง์ ‘์ ์ธ ์„ธํฌ์‚ฌ(apoptosis)์˜ ๊ธฐ์ „๋‹ค์ž˜๋ ‰์Šค๋Š” CD38์ด๋ผ๋Š” ์ˆ˜์šฉ์ฒด์— ๊ฒฐํ•ฉํ•˜๋Š”๋ฐ, ์ด CD38์€ ๋‹จ์ˆœํ•œ ๋งˆ์ปค๊ฐ€ ์•„๋‹ˆ๋ผ NAD+ ๋Œ€์‚ฌ์— ๊ด€์—ฌํ•˜๋Š” ํšจ์†Œ์ด์ž, ์‹ ํ˜ธ์ „๋‹ฌ ์ˆ˜์šฉ์ฒด ์—ญํ• ๋„ ํ•ด์š”. ๊ทธ๋ž˜์„œ ๋‹ค์Œ๊ณผ ๊ฐ™์€ ์ผ์ด ์ผ์–ด๋‚  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค:๐Ÿ’ฅ 1. CD38 cross-linking → ์„ธํฌ์‚ฌ ์œ ๋„ํ•ญ์ฒด๊ฐ€ CD38์— ๊ฒฐํ•ฉํ•˜๋ฉด, ์„ธํฌ ํ‘œ๋ฉด์˜ CD38 ๋ถ„์ž๋“ค์ด ํด๋Ÿฌ์Šคํ„ฐ๋ฅผ ์ด๋ฃจ๊ฒŒ ๋จ (cross-linking)์ด ํด๋Ÿฌ์Šคํ„ฐ๋ง์ด ์„ธํฌ ๋‚ด Ca²โบ ์‹ ํ˜ธ, R..
Field Notes/Support : Pharma
๋‹ค๋ฐœ์„ฑ๊ณจ์ˆ˜์ข… ์น˜๋ฃŒ์ œ์ธ ๋‹ค์ž˜๋ ‰์Šค๊ฐ€ CD38๋ฅผ ํƒ€๊ฒŸํ•˜๋Š” ์ด์œ ?
2025.04.26
**๋‹ค์ž˜๋ ‰์Šค(Darzalex, ์„ฑ๋ถ„๋ช… daratumumab)**๊ฐ€ CD38์„ ํƒ€๊ฒŸํ•˜๋Š” ์ด์œ ๋Š” ๋ฐ”๋กœ ๋‹ค๋ฐœ์„ฑ ๊ณจ์ˆ˜์ข…(Multiple Myeloma) ์„ธํฌ์—์„œ CD38์ด ๋งค์šฐ ๋†’๊ฒŒ ๋ฐœํ˜„๋˜๊ธฐ ๋•Œ๋ฌธ์ž…๋‹ˆ๋‹ค.โธป๐Ÿ’ก CD38์„ ํƒ€๊ฒŸํ•˜๋Š” ์ด์œ ๐Ÿ”ฌ 1. CD38์€ ๋‹ค๋ฐœ์„ฑ ๊ณจ์ˆ˜์ข… ์„ธํฌ์˜ ํ‘œ์ง€(marker) ์—ญํ•  • CD38์€ ๋ฉด์—ญ์„ธํฌ(ํŠนํžˆ B์„ธํฌ) ๋ฐ ๋‹ค์–‘ํ•œ ์„ธํฌ์— ๋ฐœํ˜„๋˜๋Š” ์„ธํฌ ํ‘œ๋ฉด ๋‹จ๋ฐฑ์งˆ์ž…๋‹ˆ๋‹ค. • ๋‹ค๋ฐœ์„ฑ ๊ณจ์ˆ˜์ข… ์„ธํฌ์—์„œ๋Š” CD38์˜ ๋ฐœํ˜„์ด ๋งค์šฐ ๋†’์Œ → ์ •์ƒ ์„ธํฌ์™€์˜ ์ฐจ๋ณ„ํ™”๋œ ํ‘œ์ ์ด ๊ฐ€๋Šฅํ•จ. • ์ด ๋•Œ๋ฌธ์— ์ •์ƒ ์กฐ์ง์—๋Š” ์ตœ์†Œํ•œ์˜ ์˜ํ–ฅ๋งŒ ์ฃผ๋ฉด์„œ, ๊ณจ์ˆ˜์ข… ์„ธํฌ๋ฅผ ์„ ํƒ์ ์œผ๋กœ ๊ณต๊ฒฉํ•  ์ˆ˜ ์žˆ์Œ.โš”๏ธ 2. CD38์„ ํ‘œ์ ์œผ๋กœ ํ•˜๋Š” ๋‹ค์–‘ํ•œ ์ž‘์šฉ ๊ธฐ์ „ • ADCC (Antibody-Dependent Cellular Cytotoxic..
Field Notes/Support : Pharma
ํ•ญ์ฒด์˜ ๋ฉด์—ญ๊ธฐ์ „ 4๊ฐ€์ง€(๋‹ค์ž˜๋ ‰์Šค ์˜ˆ์‹œ)
2025.04.26
๐Ÿง  ํ•ญ์ฒด ํ•˜๋‚˜๋กœ 4๊ฐ€์ง€ ๋ฉด์—ญ ๊ธฐ์ „์ด ํ™œ์„ฑํ™”๋˜๋Š” ์ด์œ ํ•ญ์ฒด๋Š” ๋‹จ์ˆœํžˆ “ํ‘œ์ ์— ๋ถ™๋Š”๋‹ค”๋กœ ๋๋‚˜๋Š” ๊ฒŒ ์•„๋‹ˆ๋ผ, ๋ถ™์€ ์ดํ›„์— ๋ฉด์—ญ๊ณ„๋ฅผ ์–ด๋–ป๊ฒŒ ํ™œ์„ฑํ™”ํ•˜๋А๋ƒ๊ฐ€ ํ•ต์‹ฌ์ด์—์š”. ํ•ญ์ฒด๋Š” ๋ณดํ†ต ๋‘ ๊ฐ€์ง€ ์ฃผ์š” ๋ถ€์œ„๋กœ ๊ตฌ์„ฑ๋ผ ์žˆ์–ด์š”:• Fab ์˜์—ญ: ํŠน์ • ํ•ญ์›์„ ์ธ์‹ํ•˜๊ณ  ๊ฒฐํ•ฉํ•˜๋Š” ๋ถ€๋ถ„ (ex. CD38)• Fc ์˜์—ญ: ๋ฉด์—ญ์„ธํฌ๋‚˜ ๋ณด์ฒด์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ถ€๋ถ„ → ์—ฌ๊ธฐ์„œ ๋‹ค์–‘ํ•œ ๊ธฐ์ „์ด ๊ฐˆ๋ผ์ง! ๐Ÿ”„ ๋‹ค์ž˜๋ ‰์Šค์˜ 4๊ฐ€์ง€ ์ž‘์šฉ๊ธฐ์ „ ํ๋ฆ„์ž‘์šฉ๊ธฐ์ „ํ๋ฆ„ ์š”์•ฝ์ฃผ์š” ๊ด€๋ จ ์„ธํฌ/๊ณ„ํ†ต1. ADCC (ํ•ญ์ฒด ์˜์กด ์„ธํฌ ๋…์„ฑ)๋‹ค์ž˜๋ ‰์Šค๊ฐ€ CD38์— ๊ฒฐํ•ฉ → NK์„ธํฌ๊ฐ€ FcγR ํ†ตํ•ด ์ธ์‹ → ์•”์„ธํฌ ๊ณต๊ฒฉNK ์„ธํฌ2. CDC (๋ณด์ฒด ์˜์กด ์„ธํฌ ๋…์„ฑ)Fc ๋ถ€๋ถ„์ด C1q ๋ณด์ฒด ๋‹จ๋ฐฑ์งˆ๊ณผ ๊ฒฐํ•ฉ → ๋ณด์ฒด ํ™œ์„ฑํ™” → ์„ธํฌ ์šฉํ•ด๋ณด์ฒด ์‹œ์Šคํ…œ3. ADCP (ํ•ญ์ฒด ์˜์กด ์‹์„ธํฌ ์ž‘์šฉ..
Field Notes/Support : Pharma
์ด์ƒ๋ฐ˜์‘ ๋ฐ ์‘๊ธ‰์•ฝ๋ฌผ ๊ด€๋ฆฌ
2025.04.26
๐Ÿšจ ์•ฝ๋ฌผ ์ด์ƒ๋ฐ˜์‘ & ์‘๊ธ‰์•ฝ๋ฌผ ๊ด€๋ฆฌ ์š”์•ฝ๐Ÿ”น 1. ์•ฝ๋ฌผ ์ด์ƒ๋ฐ˜์‘ (Adverse Drug Reactions, ADR)โœ… ๋ถ„๋ฅ˜์œ ํ˜• ํŠน์ง• ์˜ˆ์‹œType A (์˜ˆ์ธก ๊ฐ€๋Šฅ)์šฉ๋Ÿ‰ ์˜์กด, ํ”ํ•จ์ €ํ˜ˆ์•• (BB), ์ถœํ˜ˆ (Warfarin)Type B (์˜ˆ์ธก ๋ถˆ๊ฐ€)๋ฉด์—ญ์„ฑ, ์œ ์ „์ ์•ฝ๋ฌผ ์•Œ๋ ˆ๋ฅด๊ธฐ, SJS, DRESSโœ… ์ค‘์ฆ ๋ฉด์—ญ๋ฐ˜์‘๋ฐ˜์‘ ํŠน์ง• ์ค‘์žฌSJS/TENํ”ผ๋ถ€ ๊ดด์‚ฌ, ์ ๋ง‰ ๋ณ‘๋ณ€์›์ธ ์•ฝ๋ฌผ ์ค‘๋‹จ + ์ž…์› ์น˜๋ฃŒDRESS๋ฐœ์—ด, ๋ฆผํ”„์ ˆ ์ข…๋Œ€, ํ˜ธ์‚ฐ๊ตฌ์ฆ๊ฐ€์Šคํ…Œ๋กœ์ด๋“œ, ์•ฝ๋ฌผ ์ค‘๋‹จ์•„๋‚˜ํ•„๋ฝ์‹œ์Šค์ „์‹  ์•Œ๋ ˆ๋ฅด๊ธฐ ์‡ผํฌEpinephrine IM ์ฆ‰์‹œ ํˆฌ์—ฌ๐Ÿ”น 2. ์•ฝ๋ฌผ ์ƒํ˜ธ์ž‘์šฉ (Drug Interactions)โœ… ์ฃผ์š” ๊ธฐ์ „ํšจ์†Œ ์œ ๋„/์–ต์ œCYP3A4 ์–ต์ œ: Macrolide, Azole๊ณ„, Grapefruit์œ ๋„์ œ: Rifampin, Carbamaz..
Field Notes/Support : Pharma
์•ฝ๋ฌผ์น˜๋ฃŒํ•™ ์งˆํ™˜๋ณ„ ์ •๋ฆฌ
2025.04.26
๐Ÿซ€ ์‹ฌํ˜ˆ๊ด€๊ณ„๊ณ ํ˜ˆ์••: ACEi, ARB, Thiazide, CCB, BB์‹ฌ๋ถ€์ „: ARNI, BB, MRA, Loop ์ด๋‡จ์ œ, SGLT2iํ˜‘์‹ฌ์ฆ/์‹ฌ๊ทผ๊ฒฝ์ƒ‰: Aspirin, Clopidogrel, BB, Statin, NTG๋ถ€์ •๋งฅ: Class I–IV ํ•ญ๋ถ€์ •๋งฅ์ œ, NOAC, Warfarin๐Ÿซ ํ˜ธํก๊ธฐ์ฒœ์‹: ICS, LABA, SABA, LTRACOPD: LAMA, LABA, ICSํ๋ ด: Amoxicillin, Macrolide, Cephalosporin, Respiratory FQ๐Ÿงฌ ๋‚ด๋ถ„๋น„๋‹น๋‡จ๋ณ‘: Metformin, SGLT2i, GLP-1 RA, SU, Insulin๊ฐ‘์ƒ์„ : Methimazole, PTU, Levothyroxine๋ถ€์‹ : Hydrocortisone, Fludrocortisone, Ketoc..
Field Notes/Support : Pharma
ํ˜ธ๋ฅด๋ชฌ์ œ์ œ
2025.04.26
๐Ÿงฉ ๋‚ด๋ถ„๋น„ ์•ฝ๋ฌผ์˜ ๊ธฐ๋ณธ ์›๋ฆฌ์ฒด๋‚ด ํ˜ธ๋ฅด๋ชฌ ๋ถ€์กฑ ๋˜๋Š” ๊ณผ๋‹ค ์ƒํƒœ๋ฅผ ์กฐ์ ˆ ๋˜๋Š” ๋ณด์ถฉํ•˜๋Š” ๋ชฉ์ ์ธ์А๋ฆฐ, ๊ฐ‘์ƒ์„  ํ˜ธ๋ฅด๋ชฌ, ๋ถ€์‹ ํ”ผ์งˆ ์Šคํ…Œ๋กœ์ด๋“œ, ์„ฑํ˜ธ๋ฅด๋ชฌ ๋“ฑ์ด ์ฃผ์š” ํƒ€๊นƒ๐Ÿ’‰ ์ธ์А๋ฆฐ ๋ฐ ๊ฒฝ๊ตฌํ˜ˆ๋‹น๊ฐ•ํ•˜์ œโœ… ์ธ์А๋ฆฐ๋ถ„๋ฅ˜ ์•ฝ๋ฌผ ์ž‘์šฉ์‹œ์  / ํŠน์ง•์ดˆ์†ํšจLispro, Aspart์‹์ „ ํˆฌ์—ฌ / ๊ธ‰์† ์ž‘์šฉ์†ํšจRegular insulinIV ๊ฐ€๋Šฅ / ๊ธ‰์„ฑ ์ผ€ํ†ค์‚ฐ์ฆ์ค‘๊ฐ„ํ˜•NPH์ง€์† ๋ฐฉ์ถœ / Basal ์šฉ์ง€์†ํ˜•Glargine, Detemirํ•˜๋ฃจ 1ํšŒ / ๊ธฐ์ €์ธ์А๋ฆฐ ์—ญํ• โœ… ๊ฒฝ๊ตฌํ˜ˆ๋‹น๊ฐ•ํ•˜์ œ๊ณ„์—ด ์•ฝ๋ฌผ ๊ธฐ์ „ / ์ฃผ์˜SU์ œGlipizide, Glyburide์ธ์А๋ฆฐ ๋ถ„๋น„ ↑ / ์ €ํ˜ˆ๋‹น ์œ„ํ—˜MeglitinideRepaglinide์‹ํ›„ ํ˜ˆ๋‹น ์กฐ์ ˆ / ์งง์€ ์ž‘์šฉBiguanideMetformin๊ฐ„ ํฌ๋„๋‹น ์ƒ์„ฑ ↓ / 1์ฐจ ์•ฝ์ œ / ์ –์‚ฐ์‚ฐ์ฆ โš ๏ธTZDPiogli..
Field Notes/Support : Pharma
ํ˜ˆ์•ก์ œ์ œ
2025.04.26
๐Ÿงฉ ํ˜ˆ์•ก์‘๊ณ  ์กฐ์ ˆ ๊ฐœ์š”ํ•ญ์‘๊ณ ์ œ: ํ˜ˆ์ „ ํ˜•์„ฑ ์˜ˆ๋ฐฉ (์ •๋งฅํ˜ˆ์ „, ์‹ฌ๋ฐฉ์„ธ๋™ ๋“ฑ)ํ•ญํ˜ˆ์†ŒํŒ์ œ: ๋™๋งฅ ํ˜ˆ์ „ ์–ต์ œ (์‹ฌ๊ทผ๊ฒฝ์ƒ‰, ๋‡Œ์กธ์ค‘ ์˜ˆ๋ฐฉ ๋“ฑ)์ง€ํ˜ˆ์ œ / ์‘๊ณ ์ธ์ž: ์ถœํ˜ˆ ์‹œ ์‚ฌ์šฉ๋นˆํ˜ˆ์น˜๋ฃŒ์ œ: ์กฐํ˜ˆ ์ด‰์ง„โš ๏ธ ํ•ญ์‘๊ณ ์ œ (Anticoagulants)์•ฝ๋ฌผ ๊ธฐ์ „ ํŠน์ง• / ์ ์‘์ฆHeparin (UFH)ATIII ํ™œ์„ฑํ™” → thrombin, Xa ์–ต์ œIV / ๋ชจ๋‹ˆํ„ฐ๋ง: aPTT / ํ•ด๋…์ œ: ProtamineLMWH (Enoxaparin)Xa ์„ ํƒ์  ์–ต์ œSC ํˆฌ์—ฌ / aPTT ๋ชจ๋‹ˆํ„ฐ ๋ถˆํ•„์š”WarfarinVit K ์˜์กด ์ธ์ž ํ•ฉ์„ฑ ์–ต์ œ (II, VII, IX, X)๊ฒฝ๊ตฌ / INR ๋ชจ๋‹ˆํ„ฐ๋ง / ํ•ด๋…: Vit KDOAC (์ง์ ‘๊ฒฝ๊ตฌํ•ญ์‘๊ณ ์ œ)Rivaroxaban (Xa), Dabigatran (IIa)๊ณ ์ •์šฉ๋Ÿ‰ / ๋ชจ๋‹ˆํ„ฐ ๋ถˆํ•„์š” / ๋น ๋ฅธํšจ๊ณผ..
Field Notes/Support : Pharma
ํ˜ธํก๊ธฐ๊ณ„
2025.04.26
๐Ÿงฉ ๊ธฐ๋ณธ ์›๋ฆฌ ๋ฐ ๋ณ‘ํƒœ์ƒ๋ฆฌ์ฒœ์‹: ๋งŒ์„ฑ ์•Œ๋ ˆ๋ฅด๊ธฐ์„ฑ ์—ผ์ฆ → ๊ธฐ๋„ ๊ณผ๋ฏผ๋ฐ˜์‘ + ๊ธฐ๊ด€์ง€ ์ˆ˜์ถ•๋ชฉํ‘œ: ์—ผ์ฆ ์™„ํ™” + ๊ธฐ๊ด€์ง€ ํ™•์žฅ๋น„์—ผ: ์•Œ๋ ˆ๋ฅด๊ธฐ ํ•ญ์› ๋…ธ์ถœ → ํžˆ์Šคํƒ€๋ฏผ ๋“ฑ ์—ผ์ฆ ๋งค๊ฐœ๋ฌผ์งˆ ๋ถ„๋น„๋ชฉํ‘œ: ๋น„์ถฉํ˜ˆ ์™„ํ™”, ํžˆ์Šคํƒ€๋ฏผ ์–ต์ œ๐ŸŒช๏ธ ์ฒœ์‹ ์น˜๋ฃŒ์ œ ๋ถ„๋ฅ˜โœ… ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ๊ณ„์—ด ์•ฝ๋ฌผ ํŠน์ง•SABA (๋‹จ๊ธฐ์ž‘์šฉ β2 ํšจ๋Šฅ์ œ)Albuterol, Terbutaline๊ธฐ๋„ ๊ธ‰์† ํ™•์žฅ / ๊ธ‰์„ฑ ๋ฐœ์ž‘ 1์ฐจ์•ฝLABA (์žฅ๊ธฐ์ž‘์šฉ β2 ํšจ๋Šฅ์ œ)Salmeterol, Formoterol์œ ์ง€์น˜๋ฃŒ / ์Šคํ…Œ๋กœ์ด๋“œ ๋ณ‘์šฉ ํ•„์ˆ˜ํ•ญ์ฝœ๋ฆฐ์ œ (ํก์ž…ํ˜•)Ipratropium (SAMA), Tiotropium (LAMA)COPD ์ค‘์‹ฌ / ์ฒœ์‹ ๋ณ‘์šฉ ๊ฐ€๋ŠฅTheophyllinePDE ์–ต์ œ → cAMP ↑ → ๊ธฐ๊ด€์ง€ ํ™•์žฅํ˜‘์†Œํ•œ ์น˜๋ฃŒ์—ญ / ์‹ฌ์žฅ ๋…์„ฑ ์ฃผ์˜โœ… ํ•ญ์—ผ์ฆ์ œ๊ณ„์—ด ์•ฝ๋ฌผ..
Field Notes/Support : Pharma
์†Œํ™”๊ธฐ๊ณ„
2025.04.26
๐Ÿงฉ ๊ธฐ๋ณธ ์›๋ฆฌ ๋ฐ ์ž‘์šฉ ๊ธฐ์ „์œ„์‚ฐ ๊ณผ๋‹ค, ์—ญ๋ฅ˜์„ฑ ์‹๋„์—ผ, ๊ถค์–‘ ๋“ฑ์€ ์‚ฐ๋ถ„๋น„ ์กฐ์ ˆ ๋ฐ ์ ๋ง‰๋ณดํ˜ธ ์•ฝ๋ฌผ๋กœ ์น˜๋ฃŒ๊ตฌํ† /๋ณ€๋น„/์„ค์‚ฌ๋Š” ์œ„์žฅ๊ด€ ์šด๋™ ์กฐ์ ˆ ๋˜๋Š” ์ˆ˜์šฉ์ฒด ์–ต์ œ๋กœ ์กฐ์ ˆ๐Ÿงช ์œ„์‚ฐ๋ถ„๋น„ ์–ต์ œ์ œ์•ฝ๋ฌผ๊ตฐ ์•ฝ๋ฌผ ๊ธฐ์ „ ํŠน์ง•PPIOmeprazole, EsomeprazoleHโบ/Kโบ-ATPase ๋น„๊ฐ€์—ญ ์–ต์ œ๊ถค์–‘ 1์ฐจ ์น˜๋ฃŒ / ํšจ๊ณผ ๊ฐ•๋ ฅ / ์žฅ์šฉ์ • ํ•„์š”H2 ์ฐจ๋‹จ์ œRanitidine, FamotidineH2 ์ˆ˜์šฉ์ฒด ์ฐจ๋‹จ → ์‚ฐ ๋ถ„๋น„ ↓์•ผ๊ฐ„ ์œ„์‚ฐ๋ถ„๋น„ ์–ต์ œ / ๋‚ด์„ฑ ๋ฐœ์ƒ ๊ฐ€๋Šฅ๐Ÿ’Š ์ œ์‚ฐ์ œ (Antacids)์•ฝ๋ฌผ ๊ธฐ์ „ ์ฃผ์˜์‚ฌํ•ญMg(OH)โ‚‚์œ„์‚ฐ ์ค‘ํ™”์„ค์‚ฌ ์œ ๋ฐœ ๊ฐ€๋ŠฅAl(OH)โ‚ƒ์œ„์‚ฐ ์ค‘ํ™”๋ณ€๋น„ ์œ ๋ฐœ ๊ฐ€๋ŠฅCaCOโ‚ƒ์ค‘ํ™”์ž‘์šฉ์œ„๋ฐ˜๋™์„ฑ ์‚ฐ๋ถ„๋น„ ↑ (๋ฐ˜๋™์„ฑ ๊ณ ์‚ฐ์ฆ)๐Ÿ›ก๏ธ ์ ๋ง‰ ๋ณดํ˜ธ์ œ์•ฝ๋ฌผ ๊ธฐ์ „ ํŠน์ง•Sucralfate๊ถค์–‘๋ถ€์œ„ ์ฝ”ํŒ…์‚ฐ์„ฑํ™˜๊ฒฝ ํ•„์š” / ์•ฝ๋ฌผ ํก์ˆ˜..
Field Notes/Support : Pharma
์ˆœํ™˜๊ธฐ๊ณ„
2025.04.26
๐Ÿงฉ ๊ธฐ๋ณธ ๊ฐœ๋… ๋ฐ ์›๋ฆฌ์‹ฌํ˜ˆ๊ด€๊ณ„ ์•ฝ๋ฌผ์€ ํ˜ˆ์•• ์กฐ์ ˆ, ์‹ฌ์žฅ๊ธฐ๋Šฅ ๊ฐ•ํ™”, ๋ฆฌ๋“ฌ ์กฐ์ ˆ์„ ๋ชฉํ‘œ๋กœ ํ•จ์ฃผ์š” ํƒ€๊นƒ: RAAS ์‹œ์Šคํ…œ, ๊ต๊ฐ์‹ ๊ฒฝ, ์นผ์Š˜์ฑ„๋„, ์ด๋‡จ์ž‘์šฉ ๋“ฑ์งˆํ™˜๋ณ„ ์•ฝ๋ฌผ ๋ถ„๋ฅ˜๋Š” ์•„๋ž˜์™€ ๊ฐ™์Œ:๊ณ ํ˜ˆ์•• → ํ˜ˆ์••์„ ๋‚ฎ์ถ”๋Š” ์•ฝ๋ฌผํ˜‘์‹ฌ์ฆ → ์‚ฐ์†Œ ์ˆ˜์š”/๊ณต๊ธ‰ ๊ท ํ˜• ์กฐ์ ˆ์‹ฌ๋ถ€์ „ → ์‹ฌ๊ธฐ๋Šฅ ๋ณด์กฐ ๋ฐ ๋ฆฌ๋ชจ๋ธ๋ง ์–ต์ œ๋ถ€์ •๋งฅ → ์‹ฌ์žฅ ์ „๊ธฐ ๋ฆฌ๋“ฌ ์กฐ์ ˆ๐Ÿฉธ ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ์ œ ๋ถ„๋ฅ˜๊ณ„์—ด ์•ฝ๋ฌผ ๊ธฐ์ „ / ํŠน์ง•์ด๋‡จ์ œHydrochlorothiazide, Furosemideํ˜ˆ์žฅ๋Ÿ‰ ↓ → ํ˜ˆ์••↓ / Thiazide๋Š” ์ดˆ๊ธฐ 1์ฐจ์•ฝACEiEnalapril, LisinoprilAngiotensin II ↓ / Kโบ↑, ๊ธฐ์นจ, ๋ถ€์ข… โš ๏ธARBLosartan, Valsartan๊ธฐ์นจ ๋ถ€์ž‘์šฉ ์—†์Œ / ์ž„๋ถ€ ๊ธˆ๊ธฐCCBAmlodipine (ํ˜ˆ๊ด€ ์„ ํƒ), Verapamil ..
Field Notes/Support : Pharma
์†Œ์—ผ์ง„ํ†ต์ œ
2025.04.26
๐Ÿงฉ ๊ธฐ๋ณธ ์›๋ฆฌ ๋ฐ ์ž‘์šฉ ๊ธฐ์ „Autacoids๋Š” ์กฐ์ง ๋‚ด์—์„œ ์ƒ์„ฑ๋˜์–ด ๊ตญ์†Œ์ ์œผ๋กœ ์ž‘์šฉํ•˜๋Š” ์ƒ๋ฆฌํ™œ์„ฑ๋ฌผ์งˆ๋Œ€ํ‘œ: Histamine, Serotonin, Kinins, Prostaglandin, LeukotrieneNSAIDs๋Š” COX ์–ต์ œ๋ฅผ ํ†ตํ•ด Prostaglandin(PG) ํ•ฉ์„ฑ ์ฐจ๋‹จ → ์—ผ์ฆ, ํ†ต์ฆ, ๋ฐœ์—ด ↓๐Ÿงช Histamine (ํžˆ์Šคํƒ€๋ฏผ)์ˆ˜์šฉ์ฒด ์ž‘์šฉ ๊ด€๋ จ ์•ฝ๋ฌผH1ํ˜ˆ๊ด€ํ™•์žฅ, ํ‰ํ™œ๊ทผ ์ˆ˜์ถ•, ๊ฐ€๋ ค์›€ํ•ญํžˆ์Šคํƒ€๋ฏผ์ œ (Diphenhydramine, Loratadine)H2์œ„์‚ฐ ๋ถ„๋น„ ์ฆ๊ฐ€H2 ์ฐจ๋‹จ์ œ (Ranitidine, Famotidine)๐ŸŒก๏ธ NSAIDs (๋น„์Šคํ…Œ๋กœ์ด๋“œ ํ•ญ์—ผ์ฆ์ œ)์•ฝ๋ฌผ ํŠน์ง• ์ ์‘์ฆ / ์ฃผ์˜Aspirin๋น„๊ฐ€์—ญ์  COX ์–ต์ œ / ํ•ญํ˜ˆ์†ŒํŒ ํšจ๊ณผ๊ณ ์šฉ๋Ÿ‰: ํ•ด์—ด·์ง„ํ†ต / ์ €์šฉ๋Ÿ‰: ์‹ฌํ˜ˆ๊ด€ ์˜ˆ๋ฐฉ / ์†Œ์•„: R..
Field Notes/Support : Pharma
๊ตญ์†Œ๋งˆ์ทจ์ œ
2025.04.26
๐Ÿงฉ ๊ธฐ๋ณธ ์›๋ฆฌ ๋ฐ ์ž‘์šฉ ๊ธฐ์ „๊ตญ์†Œ๋งˆ์ทจ์ œ๋Š” Naโบ ํ†ต๋กœ ์ฐจ๋‹จ์„ ํ†ตํ•ด ์‹ ๊ฒฝ ์ „๋„๋ฅผ ์–ต์ œํ•˜์—ฌ ๊ฐ๊ฐ ์ „๋‹ฌ์„ ์ฐจ๋‹จํ•ฉ๋‹ˆ๋‹ค.ํŠนํžˆ ์ž‘์€ ์ง๊ฒฝ์˜ ๋น„์ˆ˜์ดˆ ์„ฌ์œ  (ํ†ต๊ฐ, ์˜จ๋„ ๊ฐ๊ฐ)๋ฅผ ๋จผ์ € ์–ต์ œํ•ฉ๋‹ˆ๋‹ค.์ž‘์šฉ ์ˆœ์„œ: ํ†ต๊ฐ → ์˜จ๊ฐ → ์ด‰๊ฐ → ์••๊ฐpH ๋ฏผ๊ฐ๋„: ์—ผ๊ธฐ์„ฑ ์•ฝ๋ฌผ์ด๋ผ ์—ผ์ฆ ๋ถ€์œ„์—์„œ๋Š” ํšจ๊ณผ ↓๐Ÿ”น ์•ฝ๋ฌผ ๋ถ„๋ฅ˜๊ณ„์—ด ์•ฝ๋ฌผ ๋Œ€์‚ฌ ๊ฒฝ๋กœ ํŠน์ง•Ester๊ณ„Procaine, Tetracaine, Benzocaineํ˜ˆ์žฅ cholinesterase์— ์˜ํ•ด ๋Œ€์‚ฌ์•Œ๋Ÿฌ์ง€ ๋ฐ˜์‘ ↑ (PABA ์œ ๋„์ฒด)Amide๊ณ„Lidocaine, Bupivacaine, Mepivacaine, Ropivacaine๊ฐ„ ๋Œ€์‚ฌ์•Œ๋Ÿฌ์ง€ ๋“œ๋ฌพ, ๋” ๋„๋ฆฌ ์‚ฌ์šฉ๋จ๐Ÿ”น ์ฃผ์š” ์•ฝ๋ฌผ ์š”์•ฝ์•ฝ๋ฌผ ํŠน์ง• ์šฉ๋„Lidocaine๊ฐ€์žฅ ํ”ํ•˜๊ฒŒ ์‚ฌ์šฉ, ์‹ ์†ํ•œ ์ž‘์šฉ, ์งง์€ ์ง€์†์‹œ๊ฐ„๊ตญ์†Œ ๋งˆ์ทจ, ํ•ญ๋ถ€์ •๋งฅ์ œ..
Field Notes/Support : Pharma
์ค‘์ถ”์‹ ๊ฒฝ๊ณ„
2025.04.26
๐Ÿงฉ ๊ธฐ๋ณธ ์›๋ฆฌ ๋ฐ ์ž‘์šฉ ๊ธฐ์ „์ค‘์ถ”์‹ ๊ฒฝ๊ณ„ ์•ฝ๋ฌผ์€ **๋‡Œ์™€ ์ฒ™์ˆ˜(CNS)**์— ์ž‘์šฉํ•˜์—ฌ ์‹ ๊ฒฝ์ „๋‹ฌ๋ฌผ์งˆ์˜ ์–‘ ๋˜๋Š” ์ˆ˜์šฉ์ฒด ์ž‘์šฉ์„ ์กฐ์ ˆํ•ฉ๋‹ˆ๋‹ค.์ฃผ์š” ํƒ€๊นƒ: GABA, Dopamine, Serotonin, Glutamate, NE ๋“ฑ๊ธฐ์ „๋ณ„๋กœ ํ•ญ์ •์‹ ๋ณ‘, ํ•ญ์šฐ์šธ, ํ•ญ๋ถˆ์•ˆ, ํ•ญ๊ฒฝ๋ จ, ์ˆ˜๋ฉด์ œ ๋“ฑ์œผ๋กœ ๋‚˜๋‰จ๐Ÿง  ํ•ญ์ •์‹ ๋ณ‘์•ฝ๋ฌผ (Antipsychotics)๐Ÿ’Š ์ž‘์šฉ ๊ธฐ์ „1์„ธ๋Œ€ (Typicals): D2 ์ˆ˜์šฉ์ฒด ๊ฐ•ํ•œ ๊ธธํ•ญ → EPS ↑2์„ธ๋Œ€ (Atypicals): D2 + 5-HT2A ๊ธธํ•ญ → EPS ↓๐Ÿงพ ์•ฝ๋ฌผ ๋น„๊ต๋ถ„๋ฅ˜ ์•ฝ๋ฌผ ํŠน์ง• / ๋ถ€์ž‘์šฉ1์„ธ๋Œ€Haloperidol, ChlorpromazineEPS, ๊ณ ํ”„๋กœ๋ฝํ‹ดํ˜ˆ์ฆ, NMS2์„ธ๋Œ€Clozapine๋ฌด๊ณผ๋ฆฝ๊ตฌ์ฆ, ์ฒด์ค‘ ์ฆ๊ฐ€, ์นจ๋ถ„๋น„↑ Olanzapine๋Œ€์‚ฌ์ฆํ›„๊ตฐ, ์ฒด์ค‘ ์ฆ๊ฐ€ Risperi..
Field Notes/Support : Pharma
๋ถ€๊ต๊ฐ์‹ ๊ฒฝ๊ณ„
2025.04.26
๐Ÿงฉ ๊ธฐ๋ณธ ์›๋ฆฌ ๋ฐ ์ž‘์šฉ ๊ธฐ์ „๋ถ€๊ต๊ฐ์‹ ๊ฒฝ๊ณ„๋Š” "Rest and Digest" ๊ธฐ๋Šฅ์„ ๋‹ด๋‹นํ•˜๋ฉฐ, ์•„์„ธํ‹ธ์ฝœ๋ฆฐ(ACh)์ด ์ฃผ์š” ์ „๋‹ฌ๋ฌผ์งˆ์ž…๋‹ˆ๋‹ค.ACh๋Š” Muscarinic ์ˆ˜์šฉ์ฒด(M1, M2, M3) ๋ฐ Nicotinic ์ˆ˜์šฉ์ฒด์— ์ž‘์šฉํ•ฉ๋‹ˆ๋‹ค.Muscarinic ์ˆ˜์šฉ์ฒด๋Š” **GPCR(G-protein coupled receptor)**๋กœ ๋‹ค์–‘ํ•œ ์ƒ๋ฆฌ ๋ฐ˜์‘์„ ๋งค๊ฐœํ•ฉ๋‹ˆ๋‹ค.M1 (Gq): ์œ„์žฅ๊ด€ ์ž๊ทนM2 (Gi): ์‹ฌ์žฅ ์–ต์ œM3 (Gq): ๋ถ„๋น„ ์ด‰์ง„, ์ถ•๋™ ๋“ฑ๐Ÿ”น Muscarinic ์ˆ˜์šฉ์ฒด ์ •๋ฆฌ์ˆ˜์šฉ์ฒด ๊ธฐ์ „ ์ž‘์šฉ ๋ถ€์œ„ ๊ธฐ๋ŠฅM1Gq์œ„์žฅ๊ด€์œ„์‚ฐ ๋ถ„๋น„ ์ฆ๊ฐ€, ์œ„์žฅ๊ด€ ์šด๋™↑M2Gi์‹ฌ์žฅ์‹ฌ๋ฐ•์ˆ˜ ↓, ์ „๋„ ↓M3Gqํ‰ํ™œ๊ทผ, ๋ถ„๋น„์„ ์ถ•๋™, ๋ถ„๋น„ ์ด‰์ง„, ๋ฐฉ๊ด‘ ์ˆ˜์ถ• ๋“ฑ๐Ÿ”น ์ง์ ‘ ์ฝœ๋ฆฐ์„ฑ ํšจ๋Šฅ์•ฝ (Muscarinic Agonist)์•ฝ๋ฌผ ์ž‘์šฉ ์ ์‘..
Field Notes/Support : Pharma
๊ต๊ฐ์‹ ๊ฒฝ๊ณ„
2025.04.26
๐Ÿงฉ ๊ธฐ๋ณธ ์›๋ฆฌ ๋ฐ ์ž‘์šฉ ๊ธฐ์ „๊ต๊ฐ์‹ ๊ฒฝ๊ณ„๋Š” "Fight or Flight" ๋ฐ˜์‘์„ ์กฐ์ ˆํ•˜๋Š” ์ž์œจ์‹ ๊ฒฝ๊ณ„์˜ ํ•œ ์ถ•์ž…๋‹ˆ๋‹ค.์‹ ๊ฒฝ์ „๋‹ฌ๋ฌผ์งˆ: ๋…ธ๋ฅด์—ํ”ผ๋„คํ”„๋ฆฐ(NE), ์—ํ”ผ๋„คํ”„๋ฆฐ์ˆ˜์šฉ์ฒด ์ข…๋ฅ˜: α1, α2, β1, β2 → ๊ฐ๊ฐ ๋‹ค๋ฅธ ์œ„์น˜์™€ ์ž‘์šฉ์ž‘์šฉ ๊ฒฝ๋กœ:NE๋Š” ์‹ ๊ฒฝ ๋ง๋‹จ์—์„œ ๋ถ„๋น„๋˜์–ด ํ‘œ์ ๊ธฐ๊ด€์˜ α, β ์ˆ˜์šฉ์ฒด์™€ ๊ฒฐํ•ฉ์ˆ˜์šฉ์ฒด ํ™œ์„ฑํ™” → ์„ธํฌ ๋‚ด G-protein ์—ฐ๊ณ„ ๊ธฐ์ „์„ ํ†ตํ•ด ์ƒ๋ฆฌ์  ๋ฐ˜์‘ ์œ ๋„์˜ˆ์‹œ:α1 ์ž๊ทน → ํ˜ˆ๊ด€ ์ˆ˜์ถ• → ํ˜ˆ์•• ์ƒ์Šนβ2 ์ž๊ทน → ๊ธฐ๊ด€์ง€ ํ‰ํ™œ๊ทผ ์ด์™„ → ์ฒœ์‹ ๊ฐœ์„ ๊ฐ„์ ‘ํšจ๋Šฅ์•ฝ์€ NE ๋ถ„๋น„๋ฅผ ์ด‰์ง„ํ•˜๊ฑฐ๋‚˜ ์žฌํก์ˆ˜๋ฅผ ์–ต์ œํ•˜์—ฌ ์ž‘์šฉ์„ ๊ฐ•ํ™”๐Ÿ”น ์ˆ˜์šฉ์ฒด ์ •๋ฆฌ์ˆ˜์šฉ์ฒด ๊ธฐ์ „ ์ฃผ์š” ์ž‘์šฉα1Gqํ˜ˆ๊ด€ ์ˆ˜์ถ•, ๋™๊ณต ์‚ฐ๋™, ๋ฐฉ๊ด‘ ๊ด„์•ฝ๊ทผ ์ˆ˜์ถ•α2GiNE ๋ถ„๋น„ ์–ต์ œ, ์ธ์А๋ฆฐ ๋ถ„๋น„ ์–ต์ œβ1Gs์‹ฌ๋ฐ•์ˆ˜ ๋ฐ ์ˆ˜์ถ•๋ ฅ ์ฆ๊ฐ€, ๋ ˆ๋‹Œ ๋ถ„๋น„ ์ฆ๊ฐ€β2G..
Field Notes/Support : Pharma
ENT
2025.04.26
ENTAcute Otitis Media๊ธ‰์„ฑ ์ค‘์ด์—ผ (Acute Otitis Media)์ •์˜: ์ค‘์ด๊ฐ• ๋‚ด ๊ฐ์—ผ (์†Œ์•„์—์„œ ํ”ํ•จ)์›์ธ๊ท : S. pneumoniae, H. influenzae, M. catarrhalis๐Ÿ’Š ์น˜๋ฃŒ ์š”์•ฝ1์ฐจ ์น˜๋ฃŒ Amoxicillin 80–90 mg/kg/day (๋ถ„ํ• ํˆฌ์—ฌ)์‹คํŒจ/๋ฐ˜๋ณตAmoxicillin-Clavulanate, Ceftriaxone IMํ†ต์ฆ ์กฐ์ ˆAcetaminophen, Ibuprofenํ•ญ์ƒ์ œ ์ง€์—ฐํˆฌ์—ฌ6–23๊ฐœ์›” ๊ณ ์—ด or ์–‘์ธก / 2์„ธ ์ด์ƒ ์„ ํƒ์  ๊ด€์ฐฐ ๊ฐ€๋Šฅ๐Ÿ’ก ํŽ˜๋‹ˆ์‹ค๋ฆฐ ์•Œ๋ ˆ๋ฅด๊ธฐ ์‹œ: Cefdinir, Azithromycin๐Ÿง  ์งˆ๋ณ‘ ์š”์•ฝAcute Bacterial Rhinosinusitis๊ธ‰์„ฑ ๋ถ€๋น„๋™์—ผ (Acute Bacterial Rhinosinusitis)์ •..
Field Notes/Support : Pharma
Dermatology
2025.04.26
DermatologyAtopic Dematitis์•„ํ† ํ”ผ ํ”ผ๋ถ€์—ผ (Atopic Dermatitis)์ •์˜: ๋งŒ์„ฑ ์—ผ์ฆ์„ฑ ํ”ผ๋ถ€์งˆํ™˜, ์‹ฌํ•œ ๊ฐ€๋ ค์›€ ๋™๋ฐ˜์•…ํ™”์š”์ธ: ํ”ผ๋ถ€์žฅ๋ฒฝ ์ด์ƒ, ์•Œ๋ ˆ๋ฅด๊ธฐ, ํ™˜๊ฒฝ์  ์ž๊ทน๐Ÿ’Š ์น˜๋ฃŒ ์š”์•ฝ๋‹จ๊ณ„ ์น˜๋ฃŒ๊ธฐ๋ณธ๋ณด์Šต์ œ, ์ž๊ทน ํšŒํ”ผ, ์ˆœํ•œ ํด๋ Œ์ €๊ฒฝ์ฆ~์ค‘๋“ฑ๋„Topical corticosteroids (1์ฐจ)Calcineurin ์–ต์ œ์ œ (Tacrolimus, Pimecrolimus) ์ค‘์ฆ / ๊ด‘๋ฒ”์œ„Dupilumab (IL-4R Ab) / Cyclosporine (๋‹จ๊ธฐ๊ฐ„)๊ด‘์„ ์น˜๋ฃŒ๋„ ๋ณ‘์šฉ ๊ฐ€๋Šฅ ๐Ÿ’ก ๊ตญ์†Œ ์Šคํ…Œ๋กœ์ด๋“œ → ๋ถ€์œ„·๊ฐ•๋„ ๋”ฐ๋ผ ์„ ํƒ (์–ผ๊ตด: ์ €๊ฐ•๋„)๐Ÿง  ์งˆ๋ณ‘ ์š”์•ฝPsoriasis๊ฑด์„  (Psoriasis)์ •์˜: T์„ธํฌ ๋งค๊ฐœ ์ž๊ฐ€๋ฉด์—ญ์งˆํ™˜ → ํ”ผ๋ถ€ ๊ณผ๊ฐํ™”์ฆ์ƒ: ์€๋ฐฑ์ƒ‰ ์ธ์„ค ๋™๋ฐ˜๋œ ํŒ์ƒํ™๋ฐ˜๐Ÿ’Š ์น˜๋ฃŒ ์š”์•ฝ๋‹จ..